Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-FR Version v8-EN
Language French English
Date Updated 2021-03-09 2020-06-18
Drug Identification Number 02238525 02238525
Brand name HP-PAC HP-PAC
Common or Proper name AMOXICILLIN, LANSOPRAZOLE, CLARITHROMYCIN AMOXICILLIN, LANSOPRAZOLE, CLARITHROMYCIN
Company Name TAKEDA PHARMACEUTICALS AMERICA INC TAKEDA PHARMACEUTICALS AMERICA INC
Ingredients LANSOPRAZOLE AMOXICILLIN CLARITHROMYCIN LANSOPRAZOLE AMOXICILLIN CLARITHROMYCIN
Strength(s) 30MG 500MG 500MG 30MG 500MG 500MG
Dosage form(s) KIT CAPSULE TABLET CAPSULE (DELAYED RELEASE) KIT CAPSULE TABLET CAPSULE (DELAYED RELEASE)
Route of administration ORAL ORAL ORAL ORAL
Packaging size HP PAC 7 DAY THERAPY HP PAC 7 DAY THERAPY
ATC code A02BD A02BD
ATC description DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD) DRUGS FOR PEPTIC ULCER AND GASTROESOPHAGEAL REFLUX DISEASE (GERD)
Reason for discontinuation Business reasons Business reasons
Anticipated discontinuation date
Actual discontinuation date 2021-03-08 2020-06-22
Remaining supply date 2020-06-30 2020-06-30
Discontinuation status Discontinued To be discontinued
Discontinuation decision reversal no no
Tier 3 Status No No
Information on remaining supply
Company comments Product discontinued for business reason.
Health Canada comments